FREE Account Opening + No Clearing Fees
Loading...

Aurobindo Pharma Buyback 2024 vs eClerx Services Buyback 2024

Comparision between Aurobindo Pharma Buyback 2024 and eClerx Services Buyback 2024.

Buyback Details

Aurobindo Pharma Buyback 2024 is a Tender Offer buyback proposed to list at BSE, NSE while eClerx Services Buyback 2024 is a Tender Offer proposed to list at BSE, NSE.

  Aurobindo Pharma Limited eClerx Services Limited
Logo Aurobindo Pharma Buyback 2024 Logo eClerx Services Buyback 2024 Logo
Type of Buyback Tender Offer Tender Offer
Listing At BSE, NSE BSE, NSE
Face Value ₹1 per share ₹10 per share
Buyback Price ₹1460 per share ₹2800 per share
Issue Size 51,36,986 shares 13,75,000 shares
Issue Size (Amount) ₹750.00 Crores ₹385.00 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders1 Equity Shares out of every 6 Fully paid-up Equity Shares held on the Record Date.206,250.00
General Category for all other Eligible Shareholders10 Equity Shares out of every 109 Fully paid-up Equity Shares held on the Record Date.1,168,750.00
Registrar Kfin Technologies Limited Kfin Technologies Limited
Lead Managers Axis Capital Limited Emkay Global Financial Services Ltd
Necessity of the buyback

The Buy-Back is being undertaken, inter-alia, for the following reasons:

  1. The buy-back will help the company reward its shareholders and enhance the overall return to shareholders.
  2. The buy-back is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time;
  3. The buy-back is being implemented through the tender offer route as prescribed under the buyback regulations and would involve the allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved for small shareholders.

The Buy-Back is being undertaken, inter-alia, for the following reasons:

  1. The Buy-Back will help the Company to return surplus cash to its shareholders holding ordinary shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders;
  2. The Company believes that the reservation for small shareholders would benefit a large number of public shareholders, who would get classified as "small shareholders" as per Regulation 2(i)(n) of the Buy-Back Regulations;
  3. The Buy-Back would help in improving return on equity by reducing the share capital base and increasing shareholder's value in the longer term;
  4. The Buy-Back gives an option to the shareholders holding ordinary shares of the Company, who can choose to participate and get cash in lieu of ordinary shares to be accepted under the Buy-Back offer or they may choose not to participate and benefit from a resultant increase in their percentage shareholding, post the Buy-Back offer, without additional investment; and
  5. The Buy-Back will help the Company in achieving an optimal capital structure.

Buyback Timetable

Aurobindo Pharma Buyback 2024 and eClerx Services Buyback 2024 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Aurobindo Pharma Buyback 2024 Buyback record date is Jul 30, 2024. eClerx Services Buyback 2024 Buyback record date is Jul 04, 2024.

  Aurobindo Pharma Limited eClerx Services Limited
Record Date Jul 30, 2024 Jul 04, 2024
Offer Open Date Jul 09, 2024
Offer Closure Date Jul 15, 2024
Last date for receipt of tender forms Jul 15, 2024
Finalisation of buyback
Last Date for settlment of bids Jul 22, 2024
Last Date for extinguishment of shares Jul 30, 2024

Financial Details and Other Relevent Information

Comparison of Aurobindo Pharma Buyback 2024 and eClerx Services Buyback 2024 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

  Aurobindo Pharma Limited eClerx Services Limited
Financial

Aurobindo Pharma Limited Financial Information (Restated)

Aurobindo Pharma Limited's revenue increased by 26.52% and profit after tax (PAT) rose by 59.25% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 2023
Assets2,515.402,505.88
Revenue1,126.17890.09
Profit After Tax195.41122.71
Amount in ₹ Crore

eClerx Services Limited Financial Information (Restated Consolidated)

eClerx Services Limited's revenue increased by 10.22% and profit after tax (PAT) rose by 4.61% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets2,928.972,287.74
Revenue2,991.182,713.852,184.96
Profit After Tax511.73489.18417.76
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jun-2024 2510.00 2116.00 2342.10
May-2024 2475.00 2127.10 2299.19
Apr-2024 2548.75 2320.00 2434.01
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Jun-2024 2512.00 2114.00 2341.96
May-2024 2485.00 2129.05 2298.47
Apr-2024 2549.90 2322.95 2437.33

Comments

Add a public comment...